These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 33645977)

  • 1. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture.
    Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
    bioRxiv; 2020 Nov; ():. PubMed ID: 33140049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
    Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
    Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
    Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
    J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Poli ANR; Tietjen I; Nandwana NK; Cassel J; Messick TE; Register ET; Keeney F; Rajaiah R; Verma AK; Pandey K; Acharya A; Byrareddy SN; Montaner LJ; Salvino JM
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0056224. PubMed ID: 39225484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
    Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
    Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
    Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
    bioRxiv; 2020 Jan; ():. PubMed ID: 32511378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
    Leneva I; Kartashova N; Poromov A; Gracheva A; Korchevaya E; Glubokova E; Borisova O; Shtro A; Loginova S; Shchukina V; Khamitov R; Faizuloev E
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
    Wang Y; Li P; Lavrijsen M; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
    Arch Virol; 2022 Apr; 167(4):1125-1130. PubMed ID: 35171357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
    Hu Y; Jo H; DeGrado WF; Wang J
    J Med Virol; 2022 May; 94(5):2188-2200. PubMed ID: 35080027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of itraconazole against SARS-CoV-2.
    Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
    J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
    Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
    Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33158912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
    Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
    Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
    ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
    Boras B; Jones RM; Anson BJ; Arenson D; Aschenbrenner L; Bakowski MA; Beutler N; Binder J; Chen E; Eng H; Hammond H; Hammond J; Haupt RE; Hoffman R; Kadar EP; Kania R; Kimoto E; Kirkpatrick MG; Lanyon L; Lendy EK; Lillis JR; Logue J; Luthra SA; Ma C; Mason SW; McGrath ME; Noell S; Obach RS; O' Brien MN; O'Connor R; Ogilvie K; Owen D; Pettersson M; Reese MR; Rogers TF; Rosales R; Rossulek MI; Sathish JG; Shirai N; Steppan C; Ticehurst M; Updyke LW; Weston S; Zhu Y; White KM; García-Sastre A; Wang J; Chatterjee AK; Mesecar AD; Frieman MB; Anderson AS; Allerton C
    Nat Commun; 2021 Oct; 12(1):6055. PubMed ID: 34663813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.